E. Serra‐Baldrich

European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions

Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)

Chronic nodular prurigo: Association between comorbidities, itch and quality of life

Italian S3-Guideline on the treatment of Atopic Eczema - Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Italian S3-Guideline on the treatment of Atopic Eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

First update of the living European guideline (<scp>EuroGuiDerm</scp>) on atopic eczema

Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

European guideline (<scp>EuroGuiDerm</scp>) on atopic eczema – part <scp>II</scp>: non‐systemic treatments and treatment recommendations for special <scp>AE</scp> patient populations

IFSI-guideline on chronic prurigo including prurigo nodularis

The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

Pathophysiology and management of sensitive skin: position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch (IFSI)

Cross‐European validation of the ItchyQoL in pruritic dermatoses

Position statement: topical calcineurin inhibitors in atopic dermatitis

European <scp>EADV</scp> network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools